Literature DB >> 26339402

Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.

Kunpeng Liu1, Yuan Ren1, Lijuan Pang1, Yan Qi1, Wei Jia1, Lin Tao1, Zhengyan Hu1, Jin Zhao1, Haijun Zhang2, Li Li2, Haifeng Yue3, Juan Han3, Weihua Liang4, Jianming Hu1, Hong Zou1, Xianglin Yuan3, Feng Li1.   

Abstract

Papillary renal cell carcinoma (PRCC) represents the second most common histological subtype of RCC, and comprises 2 subtypes. Prognosis for type 1 PRCC is relatively good, whereas type 2 PRCC is associated with poor clinical outcomes. The aim of the present study was to evaluate the clinicopathological and mutations characteristics of PRCC. Hence, we reported on 13 cases of PRCC analyzed using whole-exome sequencing. Histologically, type 2 PRCC showed a higher nuclear grade and lymphovascular invasion rate versus type 1 PRCC (P < 0.05). Immunostaining revealed type 1 PRCC had higher CK7 and lower Top IIα expression rates (P < 0.05). Whole-exome sequencing data analysis revealed that the mutational statuses of 373 genes (287 missense, 69 silent, 6 nonsense, and 11 synonymous mutations) differed significantly between PRCC and normal renal tissues (P < 0.05). Functional enrichment analysis was used to classify the 287 missense-mutated genes into 11 biological process clusters (comprised of 61 biological processes) and 5 pathways, involved in cell adhesion, microtubule-based movement, the cell cycle, polysaccharide biosynthesis, muscle cell development and differentiation, cell death, and negative regulation. Associated pathways included the ATP-binding cassette transporter, extracellular matrix-receptor interaction, lysosome, complement and coagulation cascades, and glyoxylate and dicarboxylate metabolism pathways. The missense mutation status of 19 genes differed significantly between the groups (P < 0.05), and alterations in the EEF1D, RFNG, GPR142, and RAB37 genes were located in different chromosomal regions in type 1 and 2 PRCC. These mutations may contribute to future studies on pathogenic mechanisms and targeted therapy of PRCC.

Entities:  

Keywords:  Papillary renal cell carcinoma; gene mutation; whole-exome sequencing

Mesh:

Substances:

Year:  2015        PMID: 26339402      PMCID: PMC4555730     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  58 in total

1.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

2.  Papillary renal cell carcinoma: a clinicopathological study of 35 cases.

Authors:  Kazuki Yamanaka; Hideaki Miyake; Isao Hara; Taka-Aki Inoue; Keisuke Hanioka; Masato Fujisawa
Journal:  Int J Urol       Date:  2006-08       Impact factor: 3.369

3.  Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma.

Authors:  Yoram Dekel; Thomas Frede; Valentina Kugel; Gad Neumann; Jens Rassweiler; Rumelia Koren
Journal:  Oncol Rep       Date:  2005-07       Impact factor: 3.906

4.  Rapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cells.

Authors:  Yangzhong Tang; James D Orth; Tiao Xie; Timothy J Mitchison
Journal:  Cancer Lett       Date:  2011-06-24       Impact factor: 8.679

5.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

Authors:  Michael S Gordon; Michael Hussey; Raymond B Nagle; Primo N Lara; Philip C Mack; Janice Dutcher; Wolfram Samlowski; Joseph I Clark; David I Quinn; Chong-Xian Pan; David Crawford
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

6.  Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.

Authors:  Matthias Waldert; Andrea Haitel; Michael Marberger; Daniela Katzenbeisser; Mehmet Ozsoy; Elisabeth Stadler; Mesut Remzi
Journal:  BJU Int       Date:  2008-09-08       Impact factor: 5.588

7.  The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma.

Authors:  Dingqi Sun; Jiaju Lu; Kejia Ding; Dongbin Bi; Zhihong Niu; Qingwei Cao; Jie Zhang; Sentai Ding
Journal:  Med Oncol       Date:  2013-02-01       Impact factor: 3.064

8.  Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC.

Authors:  Daisuke Matsuda; Sok Kean Khoo; Aaron Massie; Masatsugu Iwamura; Jindong Chen; David Petillo; Bill Wondergem; Michael Avallone; Stephanie J Kloostra; Min-Han Tan; Julie Koeman; Zhongfa Zhang; Richard J Kahnoski; Shiro Baba; Bin Tean Teh
Journal:  Cancer Lett       Date:  2008-08-03       Impact factor: 8.679

Review 9.  Epidemiology and staging of renal cell carcinoma.

Authors:  Carole A Ridge; Bradley B Pua; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

10.  Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.

Authors:  Naomi Walsh; Annemarie Larkin; Susan Kennedy; Lisa Connolly; Jo Ballot; Wei Ooi; Giuseppe Gullo; John Crown; Martin Clynes; Lorraine O'Driscoll
Journal:  BMC Urol       Date:  2009-06-24       Impact factor: 2.264

View more
  8 in total

1.  EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling.

Authors:  Dong-Dong Cheng; Shi-Jie Li; Bin Zhu; Shu-Min Zhou; Qing-Cheng Yang
Journal:  J Exp Clin Cancer Res       Date:  2018-03-06

2.  Identifying Genetic Lesions in Ocular Adnexal Extranodal Marginal Zone Lymphomas of the MALT Subtype by Whole Genome, Whole Exome and Targeted Sequencing.

Authors:  Patricia Johansson; Ludger Klein-Hitpass; Bettina Budeus; Matthias Kuhn; Chris Lauber; Michael Seifert; Ingo Roeder; Roman Pförtner; Martin Stuschke; Ulrich Dührsen; Anja Eckstein; Jan Dürig; Ralf Küppers
Journal:  Cancers (Basel)       Date:  2020-04-17       Impact factor: 6.639

Review 3.  Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.

Authors:  Nanna Bæk Møller; Cecilie Budolfsen; Daniela Grimm; Marcus Krüger; Manfred Infanger; Markus Wehland; Nils E Magnusson
Journal:  Int J Mol Sci       Date:  2019-09-23       Impact factor: 5.923

4.  Prognostic value of CDCA3 in kidney renal papillary cell carcinoma.

Authors:  Hao Li; Mi Li; Caihong Yang; Fengjing Guo; Sisi Deng; Lixi Li; Tian Ma; Jiyuan Yan; Hua Wu; Xiaojuan Li
Journal:  Aging (Albany NY)       Date:  2021-12-14       Impact factor: 5.682

Review 5.  The role of EEF1D in disease pathogenesis: a narrative review.

Authors:  Hui Xu; Shaobin Yu; Kaiming Peng; Lei Gao; Sui Chen; Zhimin Shen; Ziyang Han; Mingduan Chen; Jihong Lin; Shuchen Chen; Mingqiang Kang
Journal:  Ann Transl Med       Date:  2021-10

6.  DNA Methylation Haplotype Block Markers Efficiently Discriminate Follicular Thyroid Carcinoma from Follicular Adenoma.

Authors:  Hui Zhang; Zhenzhen Zhang; Xiaoding Liu; Huanli Duan; Tianmin Xiang; Qiye He; Zhixi Su; Huanwen Wu; Zhiyong Liang
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

7.  Overexpression of interleukin-20 receptor subunit beta (IL20RB) correlates with cell proliferation, invasion and migration enhancement and poor prognosis in papillary renal cell carcinoma.

Authors:  Xi-Feng Cui; Xi-Gang Cui; Ning Leng
Journal:  J Toxicol Pathol       Date:  2019-07-07       Impact factor: 1.628

Review 8.  Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment?

Authors:  Jesús Cosín-Roger; Dolores Ortiz-Masia; Maria Dolores Barrachina; Sara Calatayud
Journal:  Cells       Date:  2020-10-23       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.